

Table 4. Characteristics of patients who developed thrombi on TEE at repeat ablation

|           | First ablation |      |               |                   |     |            |         |         |                          |  | Days to repeat ablation |
|-----------|----------------|------|---------------|-------------------|-----|------------|---------|---------|--------------------------|--|-------------------------|
|           | Age            | Sex  | Type of AF    | Anticoagulation   | TEE | SEC on TEE | LAD, mm | LVEF, % | CHADS <sub>2</sub> score | CHA <sub>2</sub> DS <sub>2</sub> -VASc score |                         |
| Patient 1 | 44             | Male | Paroxysmal AF | Warfarin          | Yes | Grade 0    | 31.3    | 55      | 0                        | 0  | 1449                    |
| Patient 2 | 38             | Male | Persistent AF | Dabigatran 300 mg | Yes | Grade 2    | 31.3    | 33      | 1                        | 1  | 515                     |
| Patient 3 | 62             | Male | Persistent AF | Apixaban 10 mg    | Yes | Grade 0    | 51.8    | 68      | 2                        | 2  | 224                     |

Continued

| Repeat ablation   |            |                     |                    |                     |                       |                       |         |         |                          |  |                                  |  |
|-------------------|------------|---------------------|--------------------|---------------------|-----------------------|-----------------------|---------|---------|--------------------------|--|----------------------------------|--|
| Anticoagulation   | SEC on TEE | Contrast CT imaging | Inappropriate dose | Interruption of OAC | Non-paroxysmal AF/AFL | D-dimer levels, µg/mL | LAD, mm | LVEF, % | CHADS <sub>2</sub> score | CHA <sub>2</sub> DS <sub>2</sub> -VASc score | Any events before repeat session |  |
| Apixaban 10 mg    | Grade 2    | Yes*                | No                 | Yes                 | No                    | ≤0.5                  | 35.9    | 61      | 0                        | 0  | Cardioversion                    |  |
| Dabigatran 300 mg | Grade 3    | Yes**               | No                 | No                  | Yes                   | ≤0.5                  | 40.7    | 19      | 1                        | 1  | Cardioversion                    |  |
| Apixaban 5 mg     | Grade 2    | No                  | Yes                | No                  | Yes                   | ≤0.5                  | 43.7    | 58.7    | 2                        | 2  | None                             |  |

Contrast-enhanced CT performed 1 d \* and 29 d \*\* before the repeat session. AF, atrial fibrillation; AFL, atrial flutter; CT, computed tomography; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; OAC, oral anticoagulants; SEC, spontaneous echo contrast; TEE, transesophageal echocardiography.